case_images: PMC11750480_01
case_images: PD-1 inhibitor-induced plaque and nail psoriasis with erythematous, well demarcated scaly plaques (A-C) and onychodystrophy of fingernails (D).
case_images: gr1.jpg
case_images: PMC11750480_01_gr1.jpg
case_images: fig1
case_images: A-C) with grade 2 severity (using the common terminology criteria for adverse events, common terminology for cutaneous adverse events [CTCAE]). All nails were dystrophic with yellowing and thickening (Fig 1, D).
case_images: Shave biopsy demonstrating acanthosis, hypogranulosis, and parakeratosis with mounds of neutrophils in the stratum corneum. (Hematoxylin and eosin, 200x)
case_images: gr2.jpg
case_images: PMC11750480_01_gr2.jpg
case_images: fig2
case_images: Biopsy demonstrated epidermal acanthosis with hypogranulosis, mild spongiosis and parakeratosis with neutrophils in the stratum corneum (Fig 2).
case_images: Rapid improvement of PD-1 inhibitor-induced psoriasis after 2 loading doses of risankizumab, with near complete skin clearance (A) and significant improvement of onychodystrophy (B).
case_images: gr3.jpg
case_images: PMC11750480_01_gr3.jpg
case_images: fig3
case_images: Risankizumab 150 mg standard dosing was started, rapidly improving joint symptoms with near complete clearance of all skin lesions (Fig 3, A) and improved onychodystrophy (Fig 3, B).
case_images: PMC11750480_02